OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Neurology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Diplopia and Ptosis in an Older Woman	696
Somebody to Love	472
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	464
Error in Author Name	337
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	284
Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis	274
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	257
Equipping AI for Unbiased and Inclusive Neurology	244
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	241
Early vs Delayed Extubation After Thrombectomy for Acute Ischemic Stroke	239
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	233
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	226
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	225
Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials	223
Efficacy and Safety of Ecopipam for Tourette Syndrome	203
Origin of Transthyretin in Cerebral Amyloid Angiopathy	199
Automated Imaging Differentiation for Parkinsonism	186
Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio	182
Rizatriptan vs Placebo for Attacks of Vestibular Migraine	180
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	173
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	163
Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach	162
JAMA Neurology	150
JAMA Neurology	150
Is It Really Itching?	147

Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis	144
Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis	134
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	132
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers	128
The Neurologist’s Imperative in Brain Death	126
External Carotid Artery Angioplasty Based on Ultrahigh-Resolution Photon-Counting CTA	125
Thrombolysis With Tenecteplase for Minor Disabling Stroke	124
Time to Change the Current Clinical Classification of Multiple Sclerosis?	123
Time From Hospital Arrival Until Endovascular Thrombectomy and Patient-Reported Outcomes in Acute Ischemic Stroke	122
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	120
Endovascular Therapy for Basilar Occlusions—The ATTENTION Trial	120
Error in Abstract	119
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation	119
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts	119
Error in Additional Contributions	116
Histologic Anatomy of Neurocysticercosis	116
Spontaneous AICA Dissection Presenting With Isolated Audiovestibular Loss	113
Error in Figure	112
Wind Swirl Pattern on Density Spectral Array in Anti-GABAB Receptor Encephalitis With Amnestic Seizures	108
Functional Seizures—A Critical Comorbidity Overlooked in Epilepsy Research—Reply	108
Role of the X Chromosome in Alzheimer Disease Genetics	106
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology	106
Sleep Recording for the Diagnosis and Treatment of Paraplegia	105
Association of Cardiovascular Events With Spouse’s Subsequent Dementia	104
Is It Really Itching?—Reply	103
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor	102
JAMA Neurology	96
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions	94
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis	92
Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation	87
Do Neurologists Need a Goldwater Rule?	87
Five Years of Ublituximab in Multiple Sclerosis	87
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy	87
Tackling the Unmet Therapeutic Needs in Nonsurgical Treatments for Epilepsy	87
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias	86
Interhemispheric Bullet Migration—A Surgical Dilemma	86
Genetic Testing by Age at Onset in Parkinson Disease	85
Tilting at Treadmills—Pitfalls and Potential of Dementia Prevention Trials	85
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke	83
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	82
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	82
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease	79
Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core	79
Seizure Frequency Trends Over Time in Treatment-Resistant Focal Epilepsy	78
Intra-Arterial Tenecteplase After Successful Reperfusion in Large Vessel Occlusion Stroke	77
Risk Factors Associated With Late-Onset Epilepsy in Dementia and Mild Cognitive Impairment	76
JAMA Neurology	76
Error in Text	75
Perceived CTE and Suicidality—Is Perception Reality?	74
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage	73

Error in Key for Figure 3	73
A Rare Neurological Presentation of Kikuchi-Fujimoto Disease	73
Error in Figures	73
A 62-Year-Old Man With Progressive Limb Weakness, Involuntary Movements, and HyperCKemia	72
AI Devices in Neurology—Moving From Diagnosis to Prognosis	71
Visualization of Parkinsonian Tongue Tremor on Ultrasonography	71
Functional Impairment in Individuals With Prodromal or Unrecognized Parkinson Disease	71
“The Triage of Privilege” Factual Concerns	71
Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	70
The New Era of Automated Electroencephalogram Interpretation	70
The Semont-Plus Maneuver or the Epley Maneuver in Posterior Canal Benign Paroxysmal Positional Vertigo	69
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome	68
Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease	68
Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage	67
Amateur Soccer Heading and Acute Elevations in Blood-Based p-Tau217 and S100B	66
Error in Author’s Name	65
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis	64
Bibrachial Amyotrophy Due to Spontaneous Spinal Cerebrospinal Fluid Leak	64
Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome	62
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	62
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease	62
Magnetic Resonance Imaging Features of GABA-A Receptor Antibody-Mediated Encephalitis	61
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	61
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients	61
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis	60
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply	59
The Choreoathetotic Movement of Paroxysmal Nonkinesigenic Dyskinesia	59
Error in Title	59
Comparison of Perinatal Outcomes for Women With and Without Epilepsy	59
Possible Explanations for Hearing Loss in Parkinson Disease	59
Livedo Reticularis—A Presenting Sign of Neuromyelitis Optica Spectrum Disorder	59
Benefits and Risks of Periconceptional Folic Acid Supplementation	58
Reimagining the Treatment of Distal and Medium Vessel Occlusion Strokes	58
Life Expectancy for Patients With Sporadic Creutzfeldt-Jakob Disease	58
Autism and Parkinsonism—Terminology and Confounding	58
Cerebral Amyloid Angiopathy—How to Translate Updated Diagnostic Criteria for This Multifaceted Disorder to Clinical Practice?	58
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest	56
Expanding the Prion Paradigm to Include Alzheimer and Parkinson Diseases	56
Abdominal Clonus in the Setting of a T5 Spinal Cord Injury	56
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	55
Brain Imaging Biomarkers and Cognitive Outcomes in a Multidomain Lifestyle Intervention	55
Repairing Our View of Dementia	55
Choosing the Best Antiseizure Medication—Can Artificial Intelligence Help?	55
Association Between Acute Myocardial Infarction and Cognition	54
IWG and AA Criteria—Where the Differences Matter—Reply	54
SARS-CoV-2 Vaccination and Neuroimmunological Disease	54
Adverse Childhood Experiences, Toxic Stress, and Trauma-Informed Neurology	53
Burden of Central Nervous System Cancer in the United States, 1990-2021	52
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies	51
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	50
Coma Prognostication After Acute Brain Injury	50
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis	50
Addition of Nonauthor Collaborators and a Supplement	49
JAMA Neurology	48
Monogenic Stroke—Can We Overcome Nature With Nurture?	48
Views From Both Sides of the White Coat	47
The Perils and Pitfalls of Global Engagement	47
Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis—Variations in Real-World Experience—Reply	47
Error in Author Affiliation	46
Transcarotid Artery Revascularization for Stroke Prevention—Multiple Elephants in the Room	45
Gantenerumab in Dominantly Inherited Alzheimer Disease—Reply	45
Errors in Figure 2 and the Short Title	45
How Is the X Chromosome Involved in Alzheimer Disease?	45
Chronic Immune Peripheral Nerve Myelinopathies—A Plea for Precision	44
Modern Neurology Training Is Failing Outpatients	44
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors	43
GLP-1 RAs for Idiopathic Intracranial Hypertension—Time for a Trial	43
Structural Inequities for Historically Underserved Communities in the Adoption of Stroke Certification in the United States	43
A Test of the Alzheimer Disease Framework—Did It Pass?	43
The Self-Test	43
Medical Forecasting—A Skill Set Worthy of Attention	43
Hypertension With High-Risk Features in Cryptogenic Stroke	42
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	41
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis	41
Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid-β and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia	41
Exome Sequencing and the Identification of New Genes and Shared Mechanisms in Polymicrogyria	41
Visual Impairment as a Modifiable Risk Factor in Dementia Prevention and Management	41
Maternal Pregnancy Outcomes and Offspring Risk of Adult-Onset Multiple Sclerosis	41
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	40
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis	40

Aberrant Left-to-Right Fusion of the Oculomotor Nerve	40
TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis	40
Dietary Patterns and Indicators of Cognitive Function	39
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage	39
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	39
Complete Remission of Cavin-4 Immunoglobulin G Rippling Muscle Disease After Rituximab Therapy	39
JAMA Neurology	38
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man	38
Incidence and Risk Factors of Epilepsy Among Older Adults in the US Medicare Population	38
Error in Figures 2 and 3	37
Error in Open Access Status	37
Acute Ischemic Stroke Care Quality Improvement	37
JAMA Neurology	37
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	37
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	37
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis	37
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	36
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	36
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	36
CT Perfusion Imaging After Selection for Late-Window Endovascular Stroke Treatment	36
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	36
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	35
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	35
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	35
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	35
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	35
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	35
Venture Capital Investment in Neurology Companies	35
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	34
Neurologic Complications of Smallpox and Monkeypox	34
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	34
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	34
2024 Diagnostic Criteria for Multiple Sclerosis—A Unified Approach	34
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	34
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	34
Asymptomatic Carotid Stenosis—Is Medical Therapy Enough?	34
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	33
Risk Factors for Young-Onset Dementia in the UK Biobank	33
Batoclimab vs Placebo for Generalized Myasthenia Gravis	33
Cerebrospinal Fluid Biomarkers for Alzheimer Disease Among Patients With Dementia	33
A Funeral for a Neurologist	33
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	33
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	33
Entering Medicine as a Physician and a Patient	32
Intramedullary Hemorrhage Causing Quadriplegia in the Setting of a Type B Aortic Dissection	32
Association Between Use of Angiotensin Receptor Blockers and Incidence of Epilepsy in Patients With Hypertension—Reply	32
A New Dystonia Phenotype in Wilson Disease	32
Paused—A Residency Interrupted	32
Butter Yellow—A Soft Hue With Neurological Implications	32
Remembering the Physician’s Humanity—Physicians Are Humans Too	32
Rethinking the Menopause Transition and Multiple Sclerosis Progression	31
Uniform Amyloid Thresholds Across Populations	31
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke	31
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	31
Embedded Human Closed-Loop Deep Brain Stimulation for Tourette Syndrome	31
JAMA Neurology Editorial Fellowship	31
Pattern of Recurrent Nontraumatic Intracerebral Hemorrhage—Reply	31
JAMA Neurology Peer Reviewers in 2025	30
Phenoconversion in Pure Autonomic Failure	30
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms	30
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	29
Lecanemab Treatment in a Specialty Memory Clinic	29
Gene Therapy vs Cochlear Implantation in Restoring Hearing Function and Speech Perception for Individuals With Congenital Deafness	29
Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers	29
Effect of Irrigation Fluid Temperature on Recurrence in the Evacuation of Chronic Subdural Hematoma	29
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?	29
Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor	29
Kelch-Like Protein 11 Antibody-Associated Paraneoplastic Encephalitis	29
Error in Figure 2B	29
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease—Reply	28
How SAFE Is Real-world Use of Spinal Cord Stimulation Therapy for Chronic Pain?	28
Bilateral Calcification of the Meckel Cave Causing Hemicrania Continua	28
Error in Title	28
Error in Figure 1	28
Error in Figures	27
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events	27
Anticoagulation in ESUS—Back From the Dead?	27
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019	27
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection	27
Cavernous Sinus Dural Arteriovenous Fistula With Ocular Congestion and Proptosis	26
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease	26
Precision Antisense Oligonucleotide Therapy Amenability for Infantile Genetic Epilepsies	26
Combined Physiotherapy and Cognitive Behavioral Therapy for Functional Movement Disorders	25
Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database	25
Gadolinium-Enhanced Aneurysm Wall Imaging and Risk of Intracranial Aneurysm Growth or Rupture	25
JAMA Neurology	25
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases	25
Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage	25
Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome	25
JAMA Neurology—The Year in Review, 2023	25
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease	25
Neurological Teleconsultations in General Practice	25
Iatrogenic Cerebrospinal Fluid–Venous Fistula	25
Noninvasive Detection of Hippocampal Epileptiform Activity on Scalp Electroencephalogram	24
JAMA Neurology	24